TABLE 2.

Overall survival (OS) outcomes from the date of pathological diagnosis or from start of SBRT treatment

	N	Median overall survival (mo)	HRa	(95 % CI)	p value
Total	88	18.4 (15.3–21.3)
OS from date of diagnosis
Protocol patients	40	18.83 (14.8–23.8)	1.00	–
Nonprotocol patients	48	17.08 (14.6–27.2)	1.13	(0.66–1.96)	0.65
Tumor in body or tail	19	NA	1.00	–
Tumor in head, neck, or uncinate	69	17.08 (14.6–21.2)	2.00	(0.76–4.9)	0.17
Baseline ECOG 0	38	18.86 (16.7–27.2)	1.00	–
Baseline ECOG ≥ 1	50	15.34 (11.3–22.2)	1.47	(0.85–2.53)	0.16
No baseline pain	47	19.52 (16.1–27.9)	1.00	–
Baseline pain	41	15.34 (14.4–21.2)	1.58	(0.87–2.62)	0.14
Baseline CA19-9 < 168 U/µL	41	19.12 (17.1–45.2)	1.00	–
Baseline CA19-9 ≥ 168 U/µL	42	16.07 (11.0–21.3)	1.59	(0.91–2.77)	0.1
Pre-SBRT chemotherapy	77	18.83 (16.1–22.2)	0.54	(0.23–1.09)	0.1
No pre-SBRT chemotherapy	11	9.00 (8.0–45.2)	1.00
Borderline resectable	14	14.39 (11.0–45.2)	0.88	(0.31–2.49)	0.81
Locally advanced	74	18.41 (15.3–21.3)	1.00	–
Pre-SBRT stent placed	28	17.87 (11.3–45.2)	1.05	(0.58–1.89)	0.88
Pre-SBRT no stent placed	60	18.83 (14.8–22.2)	1.00	–
OS from start of SBRT
Protocol patients	40	18.2 (11.7–22.3)	1.00	–
Nonprotocol patients	48	12.7 (9.4–18.2)	1.61	(0.92–2.82)	0.09
No surgical resection	69	12.75 (9.7–18.2)	1.00
Surgical resection	19	20.24 (12.5–42.4)	0.34	(0.10–1.08)	0.07
Post SBRT ECOG 0	44	18.27 (14.6–42.4)	1.00	–
Post SBRT ECOG ≥ 1	44	11.73 (7.8–18.2)	1.56	(0.89–2.71)	0.12
Post SBRT CA19-9 < 62 U/µL	36	15.01 (12.8–24.3)	1.00	–
Post SBRT CA19-9 ≥ 62 U/µL	39	12.42 (9.2–19.9)	1.34	(0.75–2.37)	0.32
Fraction size 6.6 Gy/fx	54	13.7 (9.7–19.9)	1.00	–
Fraction size < 6.6 Gy/fx	34	13.0 (12.4–42.4)	1.12	(0.63–1.99)	0.69

^*Statistically significant (p < 0.05)

^aHazard ratios from diagnosis are adjusted for age, sex, race and a time-dependent covariate for the time between diagnosis and treatment. Hazard ratios from treatment are adjusted for age, sex, and race only